Article

PD-1 Inhibitors are a game changer

Author(s):

Guest

Michael Wong, melanoma oncologist and CURE advisory board member, explains how recent studies are targeting the PD-1 pathway and describes why there is so much excitement surrounding this new class of immunotherapy.

Related Videos
Image of man with black hair.
Image of a man with dark hair and some facial hair.
Image of a man with blond facial hair.
Three women on a Zoom call discussing tracking side effects during breast cancer treatment.
Three women on a Zoom call discussing managing side effects of breast cancer treatment.
Three women on a Zoom call discussing managing side effects during breast cancer treatment.
Related Content
Image of prostate cancer scans.
November 22nd 2024

PSMA-Targeted Radiation Drug for Prostate Cancer Subset Meets Study Goal

Ryan Scott
Patients with PSMA-positive metastatic castration-resistant prostate cancer showed benefits after receiving PSMA-targeted treatment.
ROS1+ Non-Small Cell Lung Cancer: Progress in Care
September 20th 2024

ROS1+ Non-Small Cell Lung Cancer: Progress in Care

This episode of the Cancer Horizons podcast features Dr. Jason Porter – a medical oncologist and hematologist at the West Cancer Center and Research Institute and Director of the Lung Cancer Disease research group and is sponsored by Bristol Myers Squibb.
Illustration of a woman with long curly red hair.
November 22nd 2024

When Faced With a Cancer-Related Trigger

Linda Cohen
When I am triggered by something related to the cancer I have, I start going down a negative rabbit hole but remind myself to be vigilant when this happens.
cancer horizons logo: a white microphone on a navy blue background
March 11th 2024

Oncology Approvals, Psychological Outcomes for Survivors and an Ovarian Cancer Vaccine

Alex Biese Brielle Benyon
Last week we saw some FDA approvals come through, as well as research that explored the psychosocial outcomes of individuals who survived pediatric rhabdosarcoma.
Illustration of lungs.
November 22nd 2024

Magrolimab-Chemo Combo Improves Responses in Metastatic NSCLC

Ashling Wahner
Patients with metastatic non-small cell lung cancer and high CD47 expression showed improved responses to treatment with magrolimab plus docetaxel.
Subcutaneous Keytruda plus berahyaluronidase alfa meets phase 3 trial end points in non–small cell lung cancer.
November 21st 2024

Subcutaneous Keytruda Plus Berahyaluronidase Alfa Combo Meets Phase 3 Trial End Points in NSCLC

Ryan Scott
Treatment with subcutaneous Keytruda plus berahyaluronidase alfa meets phase 3 trial end points in the treatment of metastatic non–small cell lung cancer.